Medesis Pharma
www.medesispharma.comA RADICAL CHANGE IN THE WAY DRUGS ARE DELIVERED TO TARGETS Medesis Pharma has developed a revolutionary technology providing a paradigm shift in drug delivery methodology concentrating not just on improving a drugs absorption characteristics, but also by ensuring that a drug reaches its site of action in the most efficient way possible. TROJAN HORSE DELIVERY The human body uses a variety of physiological cellular delivery mechanisms to deliver molecules essential to the workings of every cell. The Aonys® drug delivery technology is able to use these natural mechanisms to circumvent the natural barriers which drugs must overcome to reach reach their sites of action. Research Medesis is undertaking an extensive research program applying the Aonys® technology to a variety of advanced therapeutics which up to now do not have suitable delivery solutions including: - Therapeutic peptides - Antisense oligonucleotides - Heavy metal chelating agents Development Clinical development programs are ongoing for two Aonys® formulated products for the following major indications: Metabolic anomalies linked to insulin resistance (pre-diabetes) Neurodegeneration in Huntington's disease
Read moreA RADICAL CHANGE IN THE WAY DRUGS ARE DELIVERED TO TARGETS Medesis Pharma has developed a revolutionary technology providing a paradigm shift in drug delivery methodology concentrating not just on improving a drugs absorption characteristics, but also by ensuring that a drug reaches its site of action in the most efficient way possible. TROJAN HORSE DELIVERY The human body uses a variety of physiological cellular delivery mechanisms to deliver molecules essential to the workings of every cell. The Aonys® drug delivery technology is able to use these natural mechanisms to circumvent the natural barriers which drugs must overcome to reach reach their sites of action. Research Medesis is undertaking an extensive research program applying the Aonys® technology to a variety of advanced therapeutics which up to now do not have suitable delivery solutions including: - Therapeutic peptides - Antisense oligonucleotides - Heavy metal chelating agents Development Clinical development programs are ongoing for two Aonys® formulated products for the following major indications: Metabolic anomalies linked to insulin resistance (pre-diabetes) Neurodegeneration in Huntington's disease
Read moreCountry
Industry
Employees
11-50
Founded
2003
Estimated Revenue
$1,000,000 to $5,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Medical Officer ; Head of Research and Development
Email ****** @****.comPhone (***) ****-****General Secretary and Chief Financial Officer Group
Email ****** @****.comPhone (***) ****-****Administrative Manager
Email ****** @****.comPhone (***) ****-****Business Manager
Email ****** @****.comPhone (***) ****-****